A big legal victory across the Atlantic Ocean was the news propelling Moderna (MRNA 15.94%) stock to a significant price surge on Hump Day. The win by the company, best known as the producer of the Spikevax COVID vaccine, pushed its stock nearly 16% higher during the trading session. By contrast, the S&P 500 (^GSPC 1.12%) could only muster a 1.1% gain.
Earlier that day, a court in Düsseldorf, Germany ruled that a COVID patent held by Moderna had been violated by a pair of rivals, American pharmaceutical giant Pfizer and its partner, German biotech BioNTech. The two had collaborated on developing and bringing to market another go-to COVID jab during the pandemic, ultimately brand-named Comirnaty.
Those two companies will have to reach into their coffers to compensate Moderna. The court said both Pfizer and BioNTech will be required to provide information on earnings that derived from the use of the patent in question; this will be used to determine how much they'll have to pay.
The ruling is subject to appeal. None of the three companies has yet commented publicly on it.
In addition to the compensatory payment, which might end up being rather large, Moderna establishes something of a precedent with this ruling. It should carry at least some weight in similar cases, should the company care to pursue them. Regardless, on its own the German court's decision is a clear legal victory, and it gives strength to the company's most critical intellectual property.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。